Apellis Pharmaceuticals to Host a Fireside Chat at the 6th Annual Evercore ISI HealthCONx ConferenceGlobeNewsWire • 11/21/23
SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA)GlobeNewsWire • 11/04/23
Apellis Pharmaceuticals, Inc. (APLS) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/01/23
Wall Street Analysts Predict a 51.91% Upside in Apellis Pharmaceuticals, Inc. (APLS): Here's What You Should KnowZacks Investment Research • 10/26/23
Apellis Pharmaceuticals to Host Conference Call on November 1, 2023, to Discuss Third Quarter 2023 Financial ResultsGlobeNewsWire • 10/25/23
The Lancet Publishes 24-Month Results from Phase 3 Studies of SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy (GA)GlobeNewsWire • 10/20/23
How Much Upside is Left in Apellis Pharmaceuticals, Inc. (APLS)? Wall Street Analysts Think 67.65%Zacks Investment Research • 10/10/23
Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023GlobeNewsWire • 10/05/23
Apellis Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-AdministrationGlobeNewsWire • 10/02/23
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Apellis Investors of a Lead Plaintiff Deadline of October 2, 2023PRNewsWire • 10/02/23
FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmAccesswire • 10/02/23
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Apellis Pharmaceuticals, Inc. - APLSPRNewsWire • 09/29/23
APLS Investors Have Opportunity to Lead Apellis Pharmaceuticals, Inc. Securities Fraud LawsuitPRNewsWire • 09/29/23
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. (APLS)Business Wire • 09/29/23
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $500,000 to Contact the FirmAccesswire • 09/29/23
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Apellis Pharmaceuticals, Inc.(APLS) Investors of a Class Action Lawsuit and Upcoming DeadlinePRNewsWire • 09/28/23
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmAccesswire • 09/27/23